EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer

Marco A De Velasco iD, Yurie Kura iD, Kazutoshi Fujita iD, Hirotsugu Uemura iD

International Journal of Urology · 2024

DOI: 10.1111/iju.15378 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Urology, 2024. Verfasst von Marco A De Velasco und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Prostatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 211 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human prostate cancer is a heterogenous malignancy that responds poorly to immunotherapy targeting immune checkpoints. The immunosuppressive tumor microenvironment that is typical of human prostate cancer has been the main obstacle to these treatments. The effectiveness of these therapies is also hindered by acquired resistance, leading to slow progress in prostate cancer immunotherapy. Results from the highly anticipated late‐stage clinical trials of PD‐1/PD‐L1 immune checkpoint blockade in patients with advanced prostate cancer have highlighted some of the obstacles to immunotherapy. Despite the setbacks, there is much that has been learned about the mechanisms that drive resistance, and new strategies are being developed and tested. Here, we review the status of immune checkpoint blockade and the immunosuppressive tumor microenvironment and discuss factors contributing to innate and adaptive resistance to immune checkpoint blockade within the context of prostate cancer. We then examine current strategies aiming to overcome these challenges as well as prospects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsProstatic NeoplasmsMaleHumansImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

castration‐resistant prostate cancerimmune checkpoint blockadeimmune modulationimmune responseimmunotherapytumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.

ORCID-Profile: Marco A De Velasco, Yurie Kura, Kazutoshi Fujita, Hirotsugu Uemura

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

De Velasco, M. A., Kura, Y., Fujita, K., & Uemura, H. (2024). Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer. International Journal of Urology. https://doi.org/10.1111/iju.15378

Vancouver

De Velasco MA, Kura Y, Fujita K, Uemura H. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer. International Journal of Urology. 2024. doi:10.1111/iju.15378

BibTeX
@article{DeVelasco2024,
  author = {De Velasco, Marco A and Kura, Yurie and Fujita, Kazutoshi and Uemura, Hirotsugu},
  title = {Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15378}
}
Kostenlos starten →